Trials / Active Not Recruiting

Active Not RecruitingNCT03074513

Atezolizumab and Bevacizumab in Treating Patients With Rare Solid Tumors

A Phase II, Single-Arm Open-Label Study of the Combination of Atezolizumab and Bevacizumab in Rare Solid Tumors

Status: Active Not Recruiting
Phase: Phase 2
Study type: Interventional
Enrollment: 133 (actual)

Sponsor: M.D. Anderson Cancer Center · Academic / Other
Sex: All
Age: 18 Years
Healthy volunteers: Not accepted

Summary

This phase II trial studies how well atezolizumab and bevacizumab work in treating patients with rare solid tumors. Immunotherapy with monoclonal antibodies, such as atezolizumab and bevacizumab, may help the body's immune system attack the cancer, and may interfere with the ability of tumor cells to grow and spread.

Detailed description

PRIMARY OBJECTIVES: I. To evaluate the efficacy of atezolizumab when given in combination with bevacizumab (atezo bev). SECONDARY OBJECTIVES: I. To evaluate the efficacy of atezo bev. II. To evaluate the safety of atezo + bev. EXPLORATORY BIOMARKER OBJECTIVES: I. To identify biomarkers that are predictive of response to atezo bev (i.e., predictive biomarkers), are associated with progression to a more severe disease state (i.e., prognostic biomarkers), are associated with resistance to atezo bev, are associated with susceptibility to developing adverse events, can provide evidence of study treatment activity, or can increase the knowledge and understanding of disease biology. OUTLINE: Patients receive atezolizumab and bevacizumab intravenously (IV) over 60 minutes on day 1. Courses repeat every 21 days in the absence of disease progression or unacceptable toxicity. After completion of study treatment, patients are followed up every 3 months.

Conditions

Interventions

Type	Name	Description
DRUG	Atezolizumab	Given IV
BIOLOGICAL	Bevacizumab	Given IV
OTHER	Laboratory Biomarker Analysis	Correlative studies
OTHER	Pharmacological Study	Correlative studies

Timeline

Start date: 2017-03-03
Primary completion: 2027-09-30
Completion: 2027-09-30
First posted: 2017-03-08
Last updated: 2026-03-11

Locations

1 site across 1 country: United States

Regulatory

FDA-regulated drug study

Source: ClinicalTrials.gov record NCT03074513. Inclusion in this directory is not an endorsement.